{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:56:23Z","timestamp":1790920583544,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T00:00:00Z","timestamp":1305158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>This review article summarizes the results of all available clinical trials considering the use of slow\u2010release oral morphine (SROM) for opioid maintenance treatment (OMT). All studies published up to October 2010 and assessing SROM for OMT in adult patients are included. Three independent reviewers assessed the selected articles using a standardized checklist. Study design, study length and number of subjects included were recorded. Data about retention rate (proportion of participants remaining under maintenance treatment at the end of the study), quality of life, withdrawal symptoms, craving, additional drug consumption, driving capacity and adverse events were collected. We identified 13 articles corresponding to nine clinical trials considering the use of SROM for OMT. Among them, only one was a randomized trial and one was a controlled not randomized trial. All other studies were uncontrolled. Retention rates were good (from 80.6 to 95%) with SROM maintenance, but similar retention rates were obtained with methadone. Most of the studies showed that quality of life, withdrawal symptoms, craving and additional drug consumption improved with SROM. However, there was no comparison with other maintenance drugs. As most of the studies assessing SROM efficacy were uncontrolled, there is no definite evidence that SROM is an effective alternative to methadone for OMT.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2011.03923.x","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T12:01:24Z","timestamp":1295956884000},"page":"832-843","source":"Crossref","is-referenced-by-count":44,"title":["Slow\u2010release oral morphine for opioid maintenance treatment: a systematic review"],"prefix":"10.1111","volume":"71","author":[{"given":"Jeremie","family":"Jegu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Gallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,12]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"United Nations Office on Drugs and Crime.World Drug Report 2009.United Nations Publication 2009. Available athttp:\/\/www.unodc.org\/unodc\/en\/data\u2010and\u2010analysis\/WDR\u20102009.html"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1994.tb03759.x"},{"key":"e_1_2_8_4_2","volume-title":"Macro\u2010Economic Analysis of Heroin Markets in the EU and the Impact of Substitution Treatment","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2000"},{"key":"e_1_2_8_5_2","first-page":"1S20","article-title":"Economic and social effects of high\u2010dose buprenorphine substitution therapy. Six\u2010month results","volume":"153","author":"Lavignasse P","year":"2002","journal-title":"Ann Med Interne (Paris)"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb03057.x"},{"key":"e_1_2_8_7_2","volume-title":"2009 Annual Report on the State of the Drugs Problem in Europe","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2009"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0793-6"},{"key":"e_1_2_8_9_2","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Year of introduction of methadone maintenance treatment high\u2010dosage buprenorphine treatment heroine\u2010assisted treatment slow\u2010realease morphine and Suboxone.2009. Available athttp:\/\/www.emcdda.europa.eu\/stats09\/hsrtab1(last accessed 18 February 2011)."},{"key":"e_1_2_8_10_2","unstructured":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 SAnitaire des Produits de Sant\u00e9. Commission nationale des stup\u00e9fiants et des psychotropes. R\u00e9union du 23 avril 2009.2009."},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.02126.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-8-200104170-00012"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577511"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02334.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000113724"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490600754374"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826080500391845"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2005.04.011"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.001128.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01148.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00764.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00190-X"},{"key":"e_1_2_8_24_2","first-page":"904","article-title":"Slow\u2010release morphine hydrochloride for maintenance therapy of opioid dependence","volume":"114","author":"Kraigher D","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085550"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000090423"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/14659890500136972"},{"key":"e_1_2_8_28_2","first-page":"35","article-title":"Oral morphine\u2010sulfate in the treatment of opiate dependent patients","volume":"32","author":"Fischer G","year":"1996","journal-title":"Alcoholism"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub3"},{"key":"e_1_2_8_30_2","unstructured":"Directorate General for Health and Consumers.Quality of treatment services in Europe \u2013 drug treatment \u2013 situation and exchange of good practice.Directorate General for Health and Consumers Report 2008. Available athttp:\/\/ec.europa.eu\/health\/ph_determinants\/life_style\/drug\/documents\/drug_treament_frep_en.pdf"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002210"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011023431802"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00335.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2003017"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1996.tb124947.x"},{"key":"e_1_2_8_36_2","volume-title":"Reviewing Current Practice in Drug Substitution Treatment in the European Union","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2000"},{"key":"e_1_2_8_37_2","first-page":"108","article-title":"Impact of slow\u2010release oral morphine on drug abusing habits in Austria","volume":"24","author":"Beer B","year":"2010","journal-title":"Neuropsychiatry"},{"key":"e_1_2_8_38_2","unstructured":"ClinicalTrials.gov. Morphine Slow\u2010release capsultes in substitution therapy.2010. Available athttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01079117(last accessed 18 February 2011)."},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9422317.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.172.1.26"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02653.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2011.03923.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2011.03923.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:47:13Z","timestamp":1697413633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2011.03923.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1365-2125.2011.03923.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03923.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,12]]}}}